TABLE 3.
AST performance for Gram-positive organisms (pre-discrepancy testing) for the 59 analyzable runs
| Organisma | Drug/resistance phenotypeb | Category agreement [no./total (%)] | No. of errors |
||
|---|---|---|---|---|---|
| Very major | Major | Minor | |||
| CNS (n = 21) | DAP | 21/21 (100) | 0 | 0 | 0 |
| VAN | 20/20 (100) | 0 | 0 | 0 | |
| MRS | 13/15 (86.7) | 1 | 1 | 0 | |
| MLSb | 11/13 (84.6) | 1 | 1 | 0 | |
| EFS and EFM (n = 14) | AMP | 14/14 (100) | 0 | 0 | 0 |
| DAP | 12/13 (92.3) | 1 | 0 | 0 | |
| LZD | 14/14 (100) | 0 | 0 | 0 | |
| VAN | 12/14 (85.7) | 1 | 0 | 1 | |
| SAU (n = 24) | CFT | 0/0 (NA) | 0 | 0 | 0 |
| DAP | 24/24 (100) | 0 | 0 | 0 | |
| ERY | 24/24 (100) | 0 | 0 | 0 | |
| LZD | 24/24 (100) | 0 | 0 | 0 | |
| VAN | 24/24 (100) | 0 | 0 | 0 | |
| MRS | 22/22 (100) | 0 | 0 | 0 | |
| All Gram-positive organisms (n = 59) | AMP | 14/14 (100) | 0 | 0 | 0 |
| CFT | 0/0 (NA) | 0 | 0 | 0 | |
| DAP | 57/58 (98.3) | 1 | 0 | 0 | |
| ERY | 24/24 (100) | 0 | 0 | 0 | |
| LZD | 38/38 (100) | 0 | 0 | 0 | |
| VAN | 56/58 (96.6) | 1 | 0 | 1 | |
| MRS | 35/37 (94.6) | 1 | 1 | 0 | |
| MLSb | 11/13 (84.6) | 1 | 1 | 0 | |
| Overall performance | 235/242 (97.1) | 4 | 2 | 1 | |
a
CNS, coagulase-negative Staphylococcus spp.; EFS, Enterococcus faecalis; EFM, Enterococcus faecium; SAU, Staphylococcus aureus.
b
AMP, ampicillin; CFT, ceftaroline; DAP, daptomycin; ERY, erythromycin; LZD, linezolid; VAN, vancomycin; MRS, methicillin-resistant Staphylococcus; MLSb, macrolide-lincosamide-streptogrammin B resistance.